Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Efficacy and safety of high dose (≥8 mg/kg/day) daptomycin].
Parra-Ruiz J, Peña-Monje A, Tomás-Jiménez C, Pomares-Mora J, Hernández-Quero J. Parra-Ruiz J, et al. Enferm Infecc Microbiol Clin. 2011 Jun-Jul;29(6):425-7. doi: 10.1016/j.eimc.2011.02.012. Epub 2011 Apr 17. Enferm Infecc Microbiol Clin. 2011. PMID: 21501905 Spanish.
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MÁ, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales JM, De la Iglesia A, Arenas JI, García-Bujalance S, Ríos MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Pérez AB, et al. PLoS One. 2019 Aug 30;14(8):e0221231. doi: 10.1371/journal.pone.0221231. eCollection 2019. PLoS One. 2019. PMID: 31469856 Free PMC article.
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB, Chueca N, García-Deltoro M, Martínez-Sapiña AM, Lara-Pérez MM, García-Bujalance S, Aldámiz-Echevarría T, Vera-Méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-Arboledas JC, Poyato A, Téllez F, Rivero-Juárez A, Merino D, Vivancos-Gallego MJ, Rosales-Zábal JM, García F; GEHEP-004 Study Group. Pérez AB, et al. J Hepatol. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022. Epub 2019 Jul 4. J Hepatol. 2019. PMID: 31279901
Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients.
Carrero A, Berenguer J, Hontañón V, Navarro J, Hernández-Quero J, Galindo MJ, Quereda C, Santos I, Téllez MJ, Ortega E, Sanz J, Medrano LM, Pérez-Latorre L, Bellón JM, Resino S, Bermejo J, González-García J; GeSIDA 3603b Study Group. Carrero A, et al. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):292-300. doi: 10.1097/QAI.0000000000002260. J Acquir Immune Defic Syndr. 2020. PMID: 31913996
Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.
Genebat M, Vera F, Hernández-Quero J, Domingo P, Guardiola JM, Martínez-Madrid O, Martínez L, de la Llana FG, Sánchez-Villegas J, Alvarez H, Mariño A, Lluch JF, Martínez-Pérez MA, Marín J, Ruiz-Mateos E, Leal M. Genebat M, et al. Antiviral Res. 2014 Apr;104:59-61. doi: 10.1016/j.antiviral.2014.01.019. Epub 2014 Jan 31. Antiviral Res. 2014. PMID: 24491797
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use.
Gonzalez-Serna A, Macias J, Corma-Gomez A, Tellez F, Cucurull J, Real LM, Granados R, Rivero-Juarez A, Hernandez-Quero J, Merino D, Palacios R, Rios MJ, Collado A, Pineda JA. Gonzalez-Serna A, et al. Among authors: hernandez quero j. J Infect. 2022 Sep;85(3):322-326. doi: 10.1016/j.jinf.2022.06.005. Epub 2022 Jun 11. J Infect. 2022. PMID: 35700867
164 results